HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.

00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF
02:20 - EMPACT-MI: The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes
04:16 - EASY-HF: Readily available urinary sodium analysis in patients with acute decompensate Heart Failure
07:16: - Design and baseline characteristics of FINE-HEART: an integrated pooled analysis of finerenone in >19,000 participants across 3 phase III trials of HF & CKD
08:17 - Pooled Analysis of PACT-HF: Long-term sex-specific clinical outcomes and healthcare resource utilization following hospitalization for heart failure
10:12 - Cardiovascular burden of the amyloidogenic V1421 transthyretin variant in black individuals
12:32 - TITRATE-HF: Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure

Recorded on-site at HFA 2024, Lisbon.

Support: This is an independent discussion produced by Radcliffe Cardiology.